CDT

CDT Equity Inc. (CDT) - 10-K Filing Summary

Business Context and Reporting Period

Company: CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Model: Data-driven biotech development focused on identifying, enhancing, and advancing high-potential therapeutic assets (specifically deprioritized clinical-stage compounds) using AI, solid-form chemistry, and asset repositioning. The company does not intend to conduct late-stage clinical trials but aims to license assets to third parties following successful pre-clinical trials.
Key Assets: AZD1656 (Glucokinase Activator for autoimmune disorders), AZD5658, and AZD5904 (MPO Inhibitor for idiopathic male infertility), licensed from AstraZeneca.
Corporate Actions: The company effected four reverse stock splits in 2025 and early 2026 (1-for-100, 1-for-15, 1-for-8, and 1-for-25), resulting in a cumulative approximate 1-for-300,000 split. All share data is retroactively adjusted.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Expense Surge: Net loss more than doubled to $39.2 million, driven primarily by a $19.7 million increase in General and Administrative (G&A) expenses and a $1.7 million increase in R&D expenses.
• Litigation Liability: A $9.6 million litigation liability was accrued in G&A related to a High Court judgment against a subsidiary (Conduit Pharmaceuticals Limited) in favor of Strand Hanson Limited. The company sold the subsidiary to Corvus Capital (controlled by the CEO) for $7.0 million in stock/warrants to isolate the liability, but accounting rules required the subsidiary to remain consolidated.
• Related Party R&D: R&D expenses increased significantly due to $4.2 million in costs associated with agreements with Sarborg Limited (a related party providing AI/cybernetic services).
• Stock Issuances: Significant non-cash compensation expenses were recorded, including $7.0 million for the issuance of shares/warrants in the sale of the subsidiary and $1.1 million for management stock awards.
• Reverse Stock Splits: Multiple reverse stock splits were executed to maintain Nasdaq listing compliance, drastically reducing the share count and increasing per-share metrics.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The independent auditor has issued an explanatory paragraph indicating substantial doubt regarding the company's ability to continue as a going concern for at least 12 months from the filing date. The company has an accumulated deficit of $68.3 million and requires additional funding to sustain operations.
• Liquidity Plan: Management plans to fund operations through public/private equity or debt financings, including an updated At-The-Market (ATM) offering program and a new Equity Line of Credit (ELOC) entered into in January 2026. As of Dec 31, 2025, the previous ATM program was fully utilized.
• Strategic Outlook: The company continues to pursue AI-driven asset repositioning and pre-clinical trials to generate data for licensing deals. It recently entered into a transaction to acquire a 20% stake in Sarborg Limited (Feb 2026) to deepen its AI capabilities.
• Key Risks:
  • Capital Shortfall: Failure to raise additional capital could force the company to delay or terminate development programs.
  • Internal Controls: Material weaknesses in internal controls over financial reporting were identified, including lack of segregation of duties and inadequate review of significant transactions.
  • Legal Proceedings: Ongoing uncertainty regarding the enforcement of the $9.6 million Strand judgment against the company directly, despite the sale of the subsidiary.
  • Intellectual Property: Patent entitlement proceedings initiated by St George Street Capital regarding the AZD1656 co-crystal patent.

Investor Verification Checklist

• Capital Adequacy: Verify the status of the new ELOC and ATM programs to confirm if the company can meet its estimated $10 million working capital requirement for the next 12 months.
• Litigation Exposure: Monitor legal correspondence regarding the Strand Hanson judgment to determine if the company faces direct liability despite the sale of the subsidiary.
• Related Party Transactions: Scrutinize the terms and valuation of the Sarborg Limited acquisition and ongoing service agreements, given the CEO's board seat at Sarborg.
• Internal Controls: Review the remediation plan for the identified material weaknesses in internal controls to assess the reliability of future financial reporting.
• Stock Dilution: Assess the impact of recent and planned equity issuances (including the Sarborg transaction and ELOC) on existing shareholder ownership percentages.